Tegaserod for constipation-predominant irritable bowel syndrome (Q33436477)

26 July 2017

1 reference

title

Tegaserod for constipation-predominant irritable bowel syndrome (English)

1 reference

26 July 2017

main subject

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

author

Pramodini B Kale-Pradhan

object named as

Pramodini B Kale-Pradhan

series ordinal

1

0 references

Sheila M Wilhelm

object named as

Sheila M Wilhelm

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 February 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

27

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

267-277

1 reference

Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Tegaserod-induced myocardial infarction: case report and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Ischemic colitis and sumatriptan use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.2.267

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.2.267

1 reference

26 July 2017

1 reference